The invention provides a compound of Formula I, ##STR00001##
Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Described is a composition that includes: (i) a drug against tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula II,

##STR00001##

or a pharmaceutically acceptable salt thereof. The composition is useful in the treatment of tuberculosis.

Described is a composition that includes: (i) a drug against tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula II,

##STR00001##

or a pharmaceutically acceptable salt thereof. The composition is useful in the treatment of tuberculosis.

Described is a composition that includes: (i) a drug against tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula II,

##STR00001##

or a pharmaceutically acceptable salt thereof. The composition is useful in the treatment of tuberculosis.

A method of modulating hematopoietic stem cells and hematopoiesis includes administering to a subject in need thereof a 15-PGDH inhibitor.

A method of modulating hematopoietic stem cells and hematopoiesis includes administering to a subject in need thereof a 15-PGDH inhibitor.

A method of modulating hematopoietic stem cells and hematopoiesis includes administering to a subject in need thereof a 15-PGDH inhibitor.

The present disclosure provides a method for stimulating asymmetric division of at least some satellite stem cells in a patient suffering from a disease or disorder characterized by satellite cells having an inability, or a reduced ability, to assemble a functional dystrophin-associated glycoprotein complex (DGC) that results in an inability, or reduced ability, to establish cell polarity. The method includes administering to the patient a sufficient amount of an epidermal growth factor receptor (EGFR) pathway activator to stimulate asymmetric division of at least some satellite stem cells.

To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereitiafter also referred to as pemafiterate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pernafiterate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereitiafter also referred to as pemafiterate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pernafiterate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.